Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? | Zendy

Vincent Soriano | Zendy; Alan S. Perelson | Zendy; Fabien Zoulim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Author(s) -

Vincent Soriano,

Alan S. Perelson,

Fabien Zoulim

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn175

Subject(s) - virology , hepatitis b virus , drug resistance , hepatitis c virus , human immunodeficiency virus (hiv) , hepatitis b , drug , selection (genetic algorithm) , virus , medicine , hepatitis c , immunology , biology , genetics , pharmacology , artificial intelligence , computer science

The arrival of new antiviral drugs to treat chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections has given rise to great expectations along with concerns regarding the selection of drug-resistant variants. Many lessons learnt from HIV therapeutics can be helpful for designing adequate treatment strategies against viral hepatitis, the avoidance of sequential weak monotherapies being one of them. Although HIV, HBV and HCV share many biological features, including very rapid viral dynamics, distinctive characteristics explain why the speed of selection of drug resistance differs substantially between these viruses, being faster for HCV than for HIV and slower for HBV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research